SG11201402237WA - Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives - Google Patents

Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

Info

Publication number
SG11201402237WA
SG11201402237WA SG11201402237WA SG11201402237WA SG11201402237WA SG 11201402237W A SG11201402237W A SG 11201402237WA SG 11201402237W A SG11201402237W A SG 11201402237WA SG 11201402237W A SG11201402237W A SG 11201402237WA SG 11201402237W A SG11201402237W A SG 11201402237WA
Authority
SG
Singapore
Prior art keywords
dihydro
oxazine
pyrido
benzo
derivatives
Prior art date
Application number
SG11201402237WA
Inventor
Giorgio Caravatti
Sylvie Chamoin
Pascal Furet
Klemens Högenauer
Konstanze Hurth
Christoph Kalis
Karen Kammertoens
Ian Lewis
Henrik Moebitz
Alexander Baxter Smith
Nicolas Soldermann
Romain Wolf
Frédéric Zecri
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201402237WA publication Critical patent/SG11201402237WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11201402237WA 2011-12-22 2012-12-20 Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives SG11201402237WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579231P 2011-12-22 2011-12-22
PCT/IB2012/057554 WO2013093849A1 (en) 2011-12-22 2012-12-20 Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

Publications (1)

Publication Number Publication Date
SG11201402237WA true SG11201402237WA (en) 2014-09-26

Family

ID=47678928

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402237WA SG11201402237WA (en) 2011-12-22 2012-12-20 Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

Country Status (42)

Country Link
US (2) US9539260B2 (en)
EP (1) EP2794600B1 (en)
JP (1) JP5903499B2 (en)
KR (1) KR101656592B1 (en)
CN (1) CN104011045B (en)
AP (1) AP4055A (en)
AR (1) AR089424A1 (en)
AU (1) AU2012356083B2 (en)
BR (1) BR112014015103B1 (en)
CA (1) CA2859764C (en)
CL (1) CL2014001452A1 (en)
CO (1) CO6990717A2 (en)
CR (2) CR20200286A (en)
CU (1) CU20140072A7 (en)
CY (1) CY1119939T1 (en)
DK (1) DK2794600T3 (en)
EA (1) EA025322B1 (en)
EC (1) ECSP14009999A (en)
ES (1) ES2661864T3 (en)
GT (1) GT201400131A (en)
HR (1) HRP20180384T1 (en)
HU (1) HUE036953T2 (en)
IL (1) IL233117A (en)
IN (1) IN2014CN04174A (en)
JO (1) JO3398B1 (en)
LT (1) LT2794600T (en)
MA (1) MA37142B1 (en)
MX (1) MX353342B (en)
MY (1) MY170922A (en)
NO (1) NO2809782T3 (en)
PE (1) PE20141598A1 (en)
PH (1) PH12014501417A1 (en)
PL (1) PL2794600T3 (en)
PT (1) PT2794600T (en)
RS (1) RS56891B1 (en)
SG (1) SG11201402237WA (en)
SI (1) SI2794600T1 (en)
TN (1) TN2014000210A1 (en)
TW (1) TWI577674B (en)
UA (1) UA112558C2 (en)
UY (1) UY34541A (en)
WO (1) WO2013093849A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2794627T3 (en) 2011-12-22 2019-04-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CR20200286A (en) 2011-12-22 2020-09-23 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
AR089284A1 (en) 2011-12-22 2014-08-13 Galapagos Nv DIHYDROPIRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME FOR THE TREATMENT OF INFLAMMATORY DISORDERS
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE036665T2 (en) * 2012-11-26 2018-07-30 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative
TW201422625A (en) * 2012-11-26 2014-06-16 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative
CN105541698B (en) * 2015-12-23 2018-07-10 滨海康杰化学有限公司 A kind of preparation method of the bromo- 2- trifluoromethyl pyridines of 5-
GB2550437B (en) * 2016-05-20 2021-06-23 Bugworks Res Inc Heterocyclic compounds useful as anti-bacterial agents and method for production
CN111936484A (en) * 2017-12-22 2020-11-13 拉文纳制药公司 Chromenopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase
MA53219A (en) 2018-08-13 2021-11-17 Hoffmann La Roche NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
TW202039512A (en) 2018-12-06 2020-11-01 日商第一三共股份有限公司 Cycloalkane-1,3-diamine compounds
TW202112784A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Chromenopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors
MX2022002311A (en) 2019-09-12 2022-03-25 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors.
EP4061821A1 (en) * 2019-11-20 2022-09-28 F. Hoffmann-La Roche AG Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
WO2022013311A1 (en) 2020-07-15 2022-01-20 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
CN116535436B (en) * 2023-05-06 2024-04-30 遵义医科大学 Fluorine ion fluorescent probe and synthesis method and application thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
TW224941B (en) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9309716D0 (en) 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
SK398A3 (en) 1995-07-06 1998-07-08 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (en) 1996-04-12 2008-07-30 Warner-Lambert Company Irreversible inhibitors of tyrosine kinazes, pharmaceutical composition containing the same and use thereof
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0923583A1 (en) 1996-08-30 1999-06-23 Novartis AG Method for producing epothilones, and intermediate products obtained during the production process
WO1998010121A1 (en) 1996-09-06 1998-03-12 Obducat Ab Method for anisotropic etching of structures in conducting materials
EP0954315A2 (en) 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (en) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research SYNTHESIS OF EPOTHILONES, ITS INTERMEDIATE PRODUCTS AND ANALOGICAL COMPOUNDS
ATE459616T1 (en) 1998-08-11 2010-03-15 Novartis Ag ISOCHINOLINE DERIVATIVES WITH ANGIOGENESIS-INHIBITING EFFECT
KR100716272B1 (en) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 Recombinant methods and materials for producing epothilone and epothilone derivatives
SK14192000A3 (en) 1998-12-23 2001-07-10 Aventis Pharma Limited Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
EP1255743A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
PE20020544A1 (en) 2000-11-07 2002-07-30 Novartis Ag INDOLYLMALEIMIDE DERIVATIVES
JPWO2002072049A1 (en) 2001-02-27 2004-07-02 山之内製薬株式会社 Pharmaceutical composition for hair growth
AR035885A1 (en) 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
AU2003280188A1 (en) 2002-12-06 2004-06-30 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
BR0317099A (en) 2002-12-09 2005-10-25 Boardd Of Regents Of The Unive In vitro method to inhibit the function and / or proliferation of a janus tyrosine kinase 3, in vitro test method to assist in the identification of substances that are useful as therapeutic immunosuppressants, in vitro method to assist in the identification of a new immunosuppressant drug, in vitro to inhibit the function and / or proliferation of a cell expressing janus tyrosine kinase 3, use of at least one compound, isolated or purified chemical compound and pharmaceutical composition
BR0317572A (en) * 2002-12-20 2005-11-22 Warner Lambert Co Benzoxazine and its derivatives as inhibitors of pi3ks
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MXPA05010444A (en) 2003-04-03 2005-11-04 Merck Patent Gmbh Pyrrolidino-1, 2-dicarboxy -1-(phenylamide) -2-(4-(3-oxo- morpholino -4-yl)- phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases.
CA2542064A1 (en) 2003-10-24 2005-05-06 Exelixis, Inc. Tao kinase modulators and methods of use
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
CN1984906A (en) 2004-07-15 2007-06-20 日本烟草产业株式会社 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
DE102004045796A1 (en) 2004-09-22 2006-03-23 Merck Patent Gmbh Medicaments containing carbonyl compounds and their use
DE102004047254A1 (en) 2004-09-29 2006-04-13 Merck Patent Gmbh carbonyl
EP1807075A2 (en) 2004-10-12 2007-07-18 Applied Research Systems ARS Holding N.V. Pi3 kinase gamma inhibitors for the treatment of anaemia
US20080269204A1 (en) 2004-11-01 2008-10-30 Tatyana Dyakonov Compounds and Methods of Use Thereof
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
UA96736C2 (en) * 2005-09-07 2011-12-12 Мерк Сероно Са Pi3k inhibitors for the treatment of endometriosis
TWI385161B (en) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp Nitrogen-containing heterobicyclic compounds
WO2008001076A1 (en) 2006-06-26 2008-01-03 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
KR20140104060A (en) 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
EP2118087B1 (en) 2007-02-06 2012-03-28 Novartis AG Pi 3-kinase inhibitors and methods of their use
US20080221094A1 (en) 2007-03-07 2008-09-11 Harald Bluhm Metalloprotease inhibitors containing a squaramide moiety
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US20110263569A1 (en) 2007-08-22 2011-10-27 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
WO2009071895A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009157196A1 (en) 2008-06-25 2009-12-30 武田薬品工業株式会社 Amide compound
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
WO2010068881A1 (en) 2008-12-12 2010-06-17 Forest Laboratories Holdings Limited Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
EP2415767B1 (en) 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) Polymerase (PARP) Inhibitors
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
US8765940B2 (en) 2009-06-25 2014-07-01 Amgen Inc. Heterocyclic compounds and their uses
MX2012013127A (en) 2010-05-13 2012-11-30 Amgen Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors.
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
KR20120018236A (en) 2010-07-23 2012-03-02 현대약품 주식회사 Substituted pyridinyl derivatives and methods for manufacturing the same
EP2640366A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2640367A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
CN102731525A (en) 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 Benzomorpholine derivative
CR20200286A (en) 2011-12-22 2020-09-23 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
TW201422625A (en) 2012-11-26 2014-06-16 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative

Also Published As

Publication number Publication date
IL233117A0 (en) 2014-07-31
JO3398B1 (en) 2019-10-20
LT2794600T (en) 2018-02-26
GT201400131A (en) 2015-06-02
AU2012356083B2 (en) 2015-01-22
NZ624872A (en) 2015-07-31
AP2014007658A0 (en) 2014-05-31
BR112014015103B1 (en) 2022-06-28
UA112558C2 (en) 2016-09-26
EP2794600B1 (en) 2017-12-06
US20130165436A1 (en) 2013-06-27
MY170922A (en) 2019-09-18
BR112014015103A2 (en) 2020-10-27
EP2794600A1 (en) 2014-10-29
WO2013093849A1 (en) 2013-06-27
HRP20180384T1 (en) 2018-04-06
CN104011045A (en) 2014-08-27
ECSP14009999A (en) 2018-10-31
RS56891B1 (en) 2018-04-30
PL2794600T3 (en) 2018-06-29
US9539260B2 (en) 2017-01-10
TW201333000A (en) 2013-08-16
TN2014000210A1 (en) 2015-09-30
KR20140107500A (en) 2014-09-04
MA37142A2 (en) 2016-07-29
KR101656592B1 (en) 2016-09-23
IL233117A (en) 2017-02-28
PH12014501417B1 (en) 2014-09-22
AP4055A (en) 2017-03-07
MX353342B (en) 2018-01-08
AU2012356083A1 (en) 2014-06-26
MA37142B1 (en) 2019-07-31
MX2014007687A (en) 2014-07-30
CL2014001452A1 (en) 2014-10-24
ES2661864T3 (en) 2018-04-04
AR089424A1 (en) 2014-08-20
DK2794600T3 (en) 2018-03-12
UY34541A (en) 2013-09-02
PH12014501417A1 (en) 2014-09-22
EA025322B1 (en) 2016-12-30
JP5903499B2 (en) 2016-04-13
JP2015506344A (en) 2015-03-02
CR20140294A (en) 2014-08-13
US9763952B2 (en) 2017-09-19
SI2794600T1 (en) 2018-03-30
CR20200286A (en) 2020-09-23
CA2859764C (en) 2019-12-31
TWI577674B (en) 2017-04-11
MA37142A3 (en) 2018-05-31
EA201491247A1 (en) 2014-09-30
PT2794600T (en) 2018-03-13
IN2014CN04174A (en) 2015-09-04
NO2809782T3 (en) 2018-01-20
CN104011045B (en) 2016-08-24
HUE036953T2 (en) 2018-08-28
CO6990717A2 (en) 2014-07-10
US20160106753A1 (en) 2016-04-21
CU20140072A7 (en) 2014-10-02
CY1119939T1 (en) 2018-12-12
CA2859764A1 (en) 2013-06-27
PE20141598A1 (en) 2014-11-14

Similar Documents

Publication Publication Date Title
HUS2100012I1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
HK1198433A1 (en) N-acyldipeptide derivatives and their uses n-
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IL233051B (en) Anti-phf-tau-antibodies and their uses
SG10201601802YA (en) Dispiropyrrolidine derivatives
PL2686331T3 (en) Rebaudioside b and derivatives
IL247640A0 (en) Heteroarylpiperidine derivatives
IL229844B (en) Anti-psgl-1-antibodies and uses thereof
IL231950B (en) Aryl-quinoline derivatives
GB201110783D0 (en) Methods and uses
EP2721029A4 (en) Imidazopyridin-2-one derivatives
EP2688588A4 (en) Rapid and prolonged immunologic-therapeutic
GB201116774D0 (en) Uses and methods
EP2716359A4 (en) Complex and uses thereof
SI2766342T1 (en) Phenyl-guanidine derivatives
EP2693879A4 (en) Migrastatins and uses thereof
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
GB201108490D0 (en) Methods and uses
PT2734522T (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
ZA201209319B (en) Cyclopropyl-indole derivatives
GB201119443D0 (en) GoWinging Concept and patent
GB201114855D0 (en) Compounds and their issues